Knowledge-based Fragment Binding Prediction

PLoS Computational Biology

Volumn 10, Issue 4, 2014, Pages

  Tang, Grace W ^a   Altman, Russ B ^a,b  

^a Stanford University   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEXATION; FORECASTING; KNOWLEDGE BASED SYSTEMS; LEARNING SYSTEMS; MOLECULAR WEIGHT; MOLECULES; PROTEINS;

CHEMICAL SEARCHES; DRUG DISCOVERY; KNOWLEDGE BASED; LOW-MOLECULAR-WEIGHT COMPOUNDS; POTENTIAL ACTIVITIES; PROTEIN FRAGMENTS; SEARCH SPACES; SMALL MOLECULES; STRUCTURAL ENVIRONMENT; TARGET PROTEINS;

LIGANDS;

ATYPICAL PROTEIN KINASE C; BACTERIAL TOXIN; DEATH ASSOCIATED PROTEIN KINASE; DEATH ASSOCIATED PROTEIN KINASE 1; EXOTOXIN A; PROTEIN KINASE C; UNCLASSIFIED DRUG; PROTEIN; PROTEIN BINDING;

ACCURACY; ARTICLE; COMPUTER MODEL; COMPUTER PREDICTION; COMPUTER PROGRAM; INFORMATION RETRIEVAL; LIGAND BINDING; MACHINE LEARNING; MOLECULAR LIBRARY; MOLECULAR WEIGHT; PROTEIN STRUCTURE; PROTEIN TARGETING; STRUCTURE ANALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; KNOWLEDGE;

KNOWLEDGE; MODELS, MOLECULAR; PROTEIN BINDING; PROTEINS;

EID: 84901317146     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003589     Document Type: Article

References (68)

1. Pammolli F, Magazzini L, Riccaboni M, (2011) The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10: 428-438.
2. Scannell JW, Blanckley A, Boldon H, Warrington B, (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11: 191-200.
3. Hopkins AL, Groom CR, (2002) The druggable genome. Nat Rev Drug Discov 1: 727-730.
4. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG, (2012) ZINC: A Free Tool to Discover Chemistry for Biology. J Chem Inf Model 52 (7) (): 1757-68.
5. Bolton E, Wang Y, Thiessen PA, SH B (2008) PubChem: Integrated Platform of Small Molecules and Biological Activities. Annual Reports in Computational Chemistry. Washington, DC: American Chemical Society.
6. Dolle RE, (2011) Historical overview of chemical library design. Methods Mol Biol 685: 3-25.
7. Ruddigkeit L, van Deursen R, Blum LC, Reymond JL, (2012) Enumeration of 166 billion organic small molecules in the chemical universe database GDB-17. J Chem Inf Model 52: 2864-2875.
8. Bohacek RS, McMartin C, Guida WC, (1996) The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev 16: 3-50.
9. Mayr LM, Bojanic D, (2009) Novel trends in high-throughput screening. Curr Opin Pharmacol 9: 580-588.
10. Leach AR, Shoichet BK, Peishoff CE, (2006) Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem 49: 5851-5855.
11. Carr RA, Congreve M, Murray CW, Rees DC, (2005) Fragment-based lead discovery: leads by design. Drug Discov Today 10: 987-992.
12. Murray CW, Verdonk ML, Rees DC, (2012) Experiences in fragment-based drug discovery. Trends Pharmacol Sci 33: 224-232.
13. Hann MM, Leach AR, Harper G, (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 41: 856-864.
14. Hajduk PJ, Greer J, (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6: 211-219.
15. Murray CW, Blundell TL, (2010) Structural biology in fragment-based drug design. Curr Opin Struct Biol 20: 497-507.
16. Nienaber VL, Richardson PL, Klighofer V, Bouska JJ, Giranda VL, et al. (2000) Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotechnol 18: 1105-1108.
17. Blundell TL, Patel S, (2004) High-throughput X-ray crystallography for drug discovery. Curr Opin Pharmacol 4: 490-496.
18. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW, (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274: 1531-1534.
19. Villar HO, Yan J, Hansen MR, (2004) Using NMR for ligand discovery and optimization. Curr Opin Chem Biol 8: 387-391.
20. Giannetti AM, (2011) From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance. Methods Enzymol 493: 169-218.
21. Verdonk ML, Giangreco I, Hall RJ, Korb O, Mortenson PN, et al. (2011) Docking performance of fragments and druglike compounds. J Med Chem 54: 5422-5431.
22. Guvench O, MacKerell AD Jr, (2009) Computational fragment-based binding site identification by ligand competitive saturation. PLoS Comput Biol 5: e1000435.
23. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
24. Wang L, Xie Z, Wipf P, Xie XQ, (2011) Residue preference mapping of ligand fragments in the Protein Data Bank. J Chem Inf Model 51: 807-815.
25. Chan AW, Laskowski RA, Selwood DL, (2010) Chemical fragments that hydrogen bond to Asp, Glu, Arg, and His side chains in protein binding sites. J Med Chem 53: 3086-3094.
26. Xie L, Bourne PE, (2005) Functional coverage of the human genome by existing structures, structural genomics targets, and homology models. PLoS Comput Biol 1: e31.
27. Halperin I, Glazer DS, Wu S, Altman RB, (2008) The FEATURE framework for protein function annotation: modeling new functions, improving performance, and extending to novel applications. BMC Genomics 9 (Suppl 2) (): S2.
28. Le Guilloux V, Schmidtke P, Tuffery P, (2009) Fpocket: an open source platform for ligand pocket detection. BMC Bioinformatics 10: 168.
29. Laskowski RA, Luscombe NM, Swindells MB, Thornton JM, (1996) Protein clefts in molecular recognition and function. Protein Sci 5: 2438-2452.
30. An J, Totrov M, Abagyan R, (2005) Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol Cell Proteomics 4: 752-761.
31. Popoff MR, (2005) Bacterial exotoxins. Contrib Microbiol 12: 28-54.
32. Jorgensen R, Wang Y, Visschedyk D, Merrill AR, (2008) The nature and character of the transition state for the ADP-ribosyltransferase reaction. EMBO Rep 9: 802-809.
33. Yates SP, Taylor PL, Jorgensen R, Ferraris D, Zhang J, et al. (2005) Structure-function analysis of water-soluble inhibitors of the catalytic domain of exotoxin A from Pseudomonas aeruginosa. Biochem J 385: 667-675.
34. Schreiber V, Dantzer F, Ame JC, de Murcia G, (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7: 517-528.
35. Ye Y, Godzik A, (2003) Flexible structure alignment by chaining aligned fragment pairs allowing twists. Bioinformatics 19 (Suppl 2) (): ii246-255.
36. Prlic A, Bliven S, Rose PW, Bluhm WF, Bizon C, et al. (2010) Pre-calculated protein structure alignments at the RCSB PDB website. Bioinformatics 26: 2983-2985.
37. Hasegawa H, Holm L, (2009) Advances and pitfalls of protein structural alignment. Curr Opin Struct Biol 19: 341-348.
38. Inbal B, Shani G, Cohen O, Kissil JL, Kimchi A, (2000) Death-associated protein kinase-related protein 1, a novel serine/threonine kinase involved in apoptosis. Mol Cell Biol 20: 1044-1054.
39. De Diego I, Kuper J, Lehmann F, Wilmanns M (2010) X-Ray Structure of a Dap-Kinase Calmodulin Complex. Sci.Signal 3 p.RA6.
40. Ueda Y, Ogata H, Yamakawa A, Higuchi Y Complex structure of kinase domain of DAP kinase with Staurosporine.
41. Fields AP, Regala RP, (2007) Protein kinase C iota: human oncogene, prognostic marker and therapeutic target. Pharmacol Res 55: 487-497.
42. Guo H, Gu F, Li W, Zhang B, Niu R, et al. (2009) Reduction of protein kinase C zeta inhibits migration and invasion of human glioblastoma cells. J Neurochem 109: 203-213.
43. Murray NR, Fields AP, (1997) Atypical protein kinase C iota protects human leukemia cells against drug-induced apoptosis. J Biol Chem 272: 27521-27524.
44. Jin YT, Ying XX, Hu YH, Zou Q, Wang HY, et al. (2008) aPKC inhibitors might be the sensitizer of chemotherapy and adoptive immunotherapy in the treatment of hASIPa-overexpressed breast cancer. Oncol Res 17: 59-68.
45. Wang C, Shang Y, Yu J, Zhang M, (2012) Substrate recognition mechanism of atypical protein kinase Cs revealed by the structure of PKCiota in complex with a substrate peptide from Par-3. Structure 20: 791-801.
46. Kjaer S, Linch M, Purkiss A, Kostelecky B, Knowles PP, et al. (2013) Adenosine-binding motif mimicry and cellular effects of a thieno[2,3-d]pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymes. Biochem J 451: 329-342.
47. Messerschmidt A, Macieira S, Velarde M, Badeker M, Benda C, et al. (2005) Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif. J Mol Biol 352: 918-931.
48. Standaert ML, Bandyopadhyay G, Antwi EK, Farese RV, (1999) RO 31-8220 activates c-Jun N-terminal kinase and glycogen synthase in rat adipocytes and L6 myotubes. Comparison to actions of insulin. Endocrinology 140: 2145-2151.
49. Hers I, Tavare JM, Denton RM, (1999) The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett 460: 433-436.
50. Davies SP, Reddy H, Caivano M, Cohen P, (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
51. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
52. Congreve M, Carr R, Murray C, Jhoti H, (2003) A 'rule of three' for fragment-based lead discovery? Drug Discov Today 8: 876-877.
53. Koster H, Craan T, Brass S, Herhaus C, Zentgraf M, et al. (2011) A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. J Med Chem 54: 7784-7796.
54. Glazer DS, Radmer RJ, Altman RB, (2009) Improving structure-based function prediction using molecular dynamics. Structure 17: 919-929.
55. Tang GW, Altman RB, (2011) Remote thioredoxin recognition using evolutionary conservation and structural dynamics. Structure 19: 461-470.
56. Glaser F, Morris RJ, Najmanovich RJ, Laskowski RA, Thornton JM, (2006) A method for localizing ligand binding pockets in protein structures. Proteins 62: 479-488.
57. Goldenberg O, Erez E, Nimrod G, Ben-Tal N, (2009) The ConSurf-DB: pre-calculated evolutionary conservation profiles of protein structures. Nucleic Acids Res 37: D323-327.
58. Sebolt-Leopold JS, English JM, (2006) Mechanisms of drug inhibition of signalling molecules. Nature 441: 457-462.
59. Skolnick J, Gao M, (2013) Interplay of physics and evolution in the likely origin of protein biochemical function. Proc Natl Acad Sci U S A 110: 9344-9349.
60. Liu T, Altman RB, (2014) Identifying druggable targets by protein microenvironments matching: application to transcription factors. CPT Pharmacometrics Syst Pharmacol 3: e93.
61. Bleicher KH, Bohm HJ, Muller K, Alanine AI, (2003) Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2: 369-378.
62. Gao M, Skolnick J, (2013) A comprehensive survey of small-molecule binding pockets in proteins. PLoS Comput Biol 9: e1003302.
63. Kahraman A, Morris RJ, Laskowski RA, Favia AD, Thornton JM, (2010) On the diversity of physicochemical environments experienced by identical ligands in binding pockets of unrelated proteins. Proteins 78: 1120-1136.
64. Overington JP, Al-Lazikani B, Hopkins AL, (2006) How many drug targets are there? Nat Rev Drug Discov 5: 993-996.
65. Sun H, Tawa G, Wallqvist A, (2012) Classification of scaffold-hopping approaches. Drug Discov Today 17: 310-324.
66. Liu T, Altman RB, (2011) Using multiple microenvironments to find similar ligand-binding sites: application to kinase inhibitor binding. PLoS Comput Biol 7: e1002326.
67. Rahman SA, Bashton M, Holliday GL, Schrader R, Thornton JM, (2009) Small Molecule Subgraph Detector (SMSD) toolkit. J Cheminform 1: 12.
68. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, et al. (2009) BLAST+: architecture and applications. BMC Bioinformatics 10: 421.